Aytu biopharma divests u.s. rights to natesto(r) to acerus pharma

Strategic transaction provides $7.5m in non-dilutive capital and enables pediatric and adhd product focus following the recently closed merger with neos therapeutics englewood, co / accesswire / april 1, 2021 / aytu biopharma, inc. (nasdaq:aytu) a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the signing of an agreement with acerus pharmaceuticals corporation (asp)(aspcf) whereby acerus will acquire all remaining rights to natesto in the united states from aytu. in consideration, aytu will receive $7.5m in cash from acerus, which is payable in $250,000 monthly payments over 30 months.
AYTU Ratings Summary
AYTU Quant Ranking